Form 13-F position report

RANI THERAPEUTICS HLDGS INC

Reported by LASRY MARC

RANI CUSIP 753018100 Manager CIK 0001259927

Reported 62,887 shares, unchanged from the prior quarter.

Reported value 22.2%; share count 0.0% vs. the prior quarter.

Unchanged
% of reported 13F value 0.24% This manager · Q2 2024
Shares 62,887 Quarter-end amount reported
Reported value $238,971 Fair value at quarter end
Consecutive quarters held 10 Through Q2 2024

Reported position value by quarter

Reported position value by quarter

Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.

Reported position value by quarter
Date Holding Value
2022-03-31 848000
2022-06-30 649000
2022-09-30 602000
2022-12-31 602457
2023-03-31 324497
2023-06-30 259094
2023-09-30 136779
2023-12-31 208785
2024-03-31 195579
2024-06-30 238971
2024-09-30 135836
2024-12-31 86155
2025-03-31 79238
2025-06-30 32318
2025-09-30 31431

Quarterly position history

How this manager's reported quarter-end position changed over time.

15 quarters
Quarterly reported position history for RANI THERAPEUTICS HLDGS INC held by LASRY MARC.
Quarter Activity Shares Change % of reported 13F Reported value Filed Source filing
Q3 2025 Unchanged 62,887 0 (0.0%) 0.21% $31,431 2025-11-14
Q2 2025 Unchanged 62,887 0 (0.0%) 0.18% $32,318 2025-08-15
Q1 2025 Unchanged 62,887 0 (0.0%) 0.36% $79,238 2025-05-14
Q4 2024 Unchanged 62,887 0 (0.0%) 0.38% $86,155 2025-02-14
Q3 2024 Unchanged 62,887 0 (0.0%) 0.25% $135,836 2024-11-14
Q2 2024 Unchanged 62,887 0 (0.0%) 0.24% $238,971 2024-08-14
Q1 2024 Unchanged 62,887 0 (0.0%) 0.17% $195,579 2024-05-15
Q4 2023 Unchanged 62,887 0 (0.0%) 0.31% $208,785 2024-02-14
Q3 2023 Unchanged 62,887 0 (0.0%) 0.13% $136,779 2023-11-14
Q2 2023 Unchanged 62,887 0 (0.0%) 0.34% $259,094 2023-08-14
Q1 2023 Unchanged 62,887 0 (0.0%) 0.62% $324,497 2023-05-15
Q4 2022 Unchanged 62,887 0 (0.0%) 0.94% $602,457 2023-02-14
Q3 2022 Added 62,887 +59 (0.1%) 1.16% $602,000 2022-11-14
Q2 2022 Unchanged 62,828 0 (0.0%) 0.99% $649,000 2022-08-15
Q1 2022 New 62,828 +62,828 (0.0%) 0.42% $848,000 2022-05-17

Who else reported the position

41 managers reported RANI THERAPEUTICS HLDGS INC for Q2 2024.

Managers reporting RANI THERAPEUTICS HLDGS INC in Q2 2024.
Manager Activity Shares Change % of reported 13F Reported value Tenure
VANGUARD GROUP INC Added 709,828 +24,525 < 0.01% $2,697,347 12 qtrs
Nan Fung Group Holdings Ltd Unchanged 493,584 0 2.0% $1,875,619 12 qtrs
Alphabet Inc Unchanged 448,492 0 0.09% $1,704,270 10 qtrs
UNITED SERVICES AUTOMOBILE ASSOCIATION Reduced 312,095 -169,205 0.03% $1,185,961 10 qtrs
TAKEDA PHARMACEUTICAL CO LTD Reduced 215,172 -123,507 0.35% $817,654 3 qtrs
GEODE CAPITAL MANAGEMENT LLC Added 150,734 +19,828 < 0.01% $572,922 12 qtrs
STIFEL FINANCIAL CORP Added 134,620 +2,186 < 0.01% $511,556 12 qtrs
Bank of America Corporation Reduced 91,846 -32,659 < 0.01% $349,015 12 qtrs
BRIDGEWAY CAPITAL MANAGEMENT LLC Added 71,500 +20,000 < 0.01% $271,700 4 qtrs
BlackRock Inc Unchanged 63,583 0 < 0.01% $241,615 11 qtrs
Premium adds each manager's conviction percentile across reporting peers.
Filing details and methodology As reported
Report period
June 30, 2024
Filed
August 14, 2024
Filing type
13F-HR
Position type
COM CL A

Voting authority reported

Sole
62,887
Shared
0
None
0

“None” means the manager reported no voting authority for those shares on non-routine matters. It does not disclose why and is not evidence of securities lending.

Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.